← Back to Clinical Trials
Recruiting NCT06701214

The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository

Trial Parameters

Condition Clonal Hematopoiesis
Sponsor Vanderbilt-Ingram Cancer Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 800
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-10-28
Completion 2030-11-30
Interventions
Blood collectionSaliva collectionBone marrow collection

Brief Summary

This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.

Eligibility Criteria

Inclusion Criteria: * Patient greater than or equal to 18 years old at time of consent * Able to provide informed consent * Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease) Exclusion Criteria: * Unable to provide consent * Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)

Related Trials